New Cancer Websites, New Features Join the Information Highway

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 6
Volume 6
Issue 6

WASHINGTON--Cancer advocacy groups, institutions, publishers, and professional organizations are rapidly making the World Wide Web a major source of cancer and other health-related information.

WASHINGTON--Cancer advocacy groups, institutions, publishers, and professionalorganizations are rapidly making the World Wide Web a major source of cancerand other health-related information.

A new government web site called "healthfinder" (http://healthfinder.gov)offers hyperlinks to more than 550 other web sites, as well as links tonearly 500 selected on-line documents, answers to often-asked questions,and access to data bases and web search engines by topic and agency.

The full text of all manuscripts in the American Cancer Society journalCancer is now available on-line free of charge until August 31,1997, at http://journals.wiley.com/cancer. After that date, access to fulltexts will be available only to paid subscribers of the print version,but abstracts and tables of contents will remain open to all.

George Washington University Medical Center's 1997 Frontiers in BiomedicineGrand Rounds lectures are available on GlaxoWellcome Healthcare Education'sHELIX site at www.helix.com.

The Oncology Nursing Society has added an oncology news applicationto its website (http://www.ons.org), offering daily wire stories, pressreleases, and original coverage of oncology and general medical news collectedfrom hundreds of national and international sources. The news service isbeing supported by a grant from Pharmacia & Upjohn.

Finally, additional features are being added to PRR Inc.'s Cancer InformationNetwork site (www.cancernetwork.com), including a daily version of OncologyNews International and hyperlinks to over 600 cancer-related websites.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content